Profile Response Detail

Molecular Profile ERBB2 L869R
Therapy Erlotinib
Indication/Tumor Type lung adenocarcinoma
Response Type resistant
Create By tyin
Update By tyin

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 L869R lung adenocarcinoma resistant Erlotinib Clinical Study Actionable In a clinical study, ERBB2 (HER2) L869R conferred resistant to ERBB2 (HER2)-directed therapy including Tarceva (erlotinib) and Tykerb (lapatinib) in a patient with lung adenocarcinoma (PMID: 27900369). 27900369
PubMed Id Reference Title Details
(27900369) Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Full reference...